Poster to Highlight Host Cell Protein (HCP) Identification and Quantification Using Mass Spectrometry – ProteoCarta™ HCP Detect
MONTREAL, Feb. 16, 2017 /PRNewswire/ -- Caprion Biosciences Inc. announced today it has presented a poster at the 4th Biologic Manufacturing Asia, Singapore. The poster features mass spectrometry and its role in greater orthogonal characterization of host cell protein impurities (HCP) during manufacturing and process development of biologics and biosimilars. The results demonstrate that extensive fractionation increases HCP coverage and clearance during DS purification.
Caprion Biosciences ProteoCarta HCP Detect offers a comprehensive technology platform which includes an unbiased discovery workflow (LC-MS/MS) and targeted MRM mass spectrometry assay using heavy isotope-labeled standards for quantification accuracy. Our mass spectrometry platform can be used for multiple HCP studies such as characterization of in-process samples and DS, HCP clearance, characterization of HCP from DS expressed in various host expression systems and comparability studies of biosimilars to biologics stated Dr. Laura McIntosh, Vice-President, Translation Research who added: "We will also be presenting additional results at the 3rd Annual Biologics & Biosimilar Congress in Berlin next March.
Poster presentation at the conference
"High Coverage Process Specific HCP Identification and Quantification Using Mass Spectrometry"
Caprion Biosciences Inc, Montreal, Quebec, Canada
Conference: Biologic Manufacturing Asia, February 15th to 16th, 2017, Booth 9
About Caprion Biosciences, Inc.
Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Caprion's immune monitoring division, ImmuneCarta®, offers proprietary multiparametric flow cytometry services for functional analyses of innate and adaptive immune responses. Caprion's proteomics division, ProteoCarta™, offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Based in Montreal, Canada, and Belgium, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 15 years. Caprion, a privately-held company, is majority owned by Global Healthcare Opportunities, or GHO Capital Partners LLP. For more information, please visit www.caprion.com.
Media Contact
Carol Berry
Chief Business Officer, SVP
Caprion Bioscience
cberry@caprion.com
514.360.3600
RELATED LINKS:
http://www.caprion.com
